Pharmacovigilance – News and Features

Pharmatek now offers contract cytotoxic & high- potent analytical, formulation and manufacturing services.

Quark's siRNA compounds for acute hearing loss slated for IND filing by year- end 2007.

The agreement provides Abraxis with the exclusive property rights for technologies designed to generate therapeutics and identify new drug discovery targets.

Quark to initiate Phase 1 trial of AKIi-5 as the first human clinical study involving the systemic delivery of siRNA.

Under the terms of the agreement, SMi will continue to operate as a wholly-owned subsidiary of CTI, utilizing its genomic-based platform to guide development of CTI's oncology products.

As part of a series of planned expansions, MPI Research announces the immediate availability of additional toxicology capacity.

In an interview published in The Wall Street the executives gave their views about moving quickly into a global leadership position in the emerging field of regenerative medicine with the company's stem cell-enabling therapeutic products and devices.

Genzyme completes its phase 3 trial of Mozobil™ in non-Hodgkin’s lymphoma, and the trial has robustly met its primary and secondary endpoints.

The grant will continue a closely-watched clinical trial involving an experimental bone marrow stem cell transplant therapy at MS Society of Canada.

CENiMED, BioTeZ and Invitek announce their cooperation to develop, produce and market the Recovery-ELISAs for the therapy control of humanized antibodies.